Myriad Genetics, Inc. (MYGN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$3.19-1.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Broken: Primary pillar broken — Maintain adjusted gross margin of 68%-69% in 2026: FY26 GM guidance 66.5% vs 68% target.
Myriad aims for $860M to $880M revenue in 2026. Gross margin should stay near 68%-69%. Adjusted EBITDA is targeted between $37M and $49M. The company is improving after past losses.
Revenue growth is slow and quarterly sales fell recently. The company is still losing money. Key executives left, which may hurt progress.
The market expects about 8% revenue growth. Our fair value is $32.53, showing the stock is cheap versus peers. We see risk in execution and profit recovery.
Breaks if: Adjusted EBITDA falls below $37M in FY26
Breaks if: Gross margin falls below 68% in FY26
Breaks if: Additional key executive departures occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity in the healthcare sector. The current thesis state is weakened, as recent financial results have not met expectations and the company's performance has slipped compared to peers.
The market currently prices MYGN as a low-risk investment with a justified valuation, suggesting that it is seen as relatively cheap compared to its peers. However, there is a slight expectations gap, indicating that the market anticipates modest improvements.
Management has prioritized growth in the Cancer Care Continuum business, but recent results show mixed delivery with volume growth and revenue pressure. The near-term risk is elevated, with a significant probability of missing earnings expectations, which has been a trend in recent quarters.
The long-term thesis hinges on management's ability to execute on growth initiatives and improve organizational efficiency. Additionally, the performance of sector bellwethers and overall economic conditions will play a crucial role in shaping MYGN's trajectory.
The most important moves since the prior daily snapshot.
Valuation fell by 18.1 points (from 70.0 to 51.9).
Yes, our read has weakened. The company cut its revenue outlook recently. This indicates significant business weakness. The latest earnings miss also contributed to this change.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $818M in FY26
The company aims to achieve a revenue range of $860 million to $880 million for the fiscal year 2026.
In the next 1 to 3 years, MYGN's performance will depend on management execution and external market conditions. Not investment advice.